1. Home
  2. UVV vs DBVT Comparison

UVV vs DBVT Comparison

Compare UVV & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Corporation

UVV

Universal Corporation

HOLD

Current Price

$53.15

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$20.53

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVV
DBVT
Founded
1886
2002
Country
United States
France
Employees
N/A
90
Industry
Farming/Seeds/Milling
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
UVV
DBVT
Price
$53.15
$20.53
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$31.75
AVG Volume (30 Days)
171.6K
213.3K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
6.22%
N/A
EPS Growth
N/A
N/A
EPS
3.02
N/A
Revenue
$2,922,924,000.00
$4,151,000.00
Revenue This Year
$0.67
$65.50
Revenue Next Year
$0.10
$47.02
P/E Ratio
$17.46
N/A
Revenue Growth
7.40
N/A
52 Week Low
$49.96
$3.91
52 Week High
$67.33
$26.19

Technical Indicators

Market Signals
Indicator
UVV
DBVT
Relative Strength Index (RSI) 47.11 45.16
Support Level $51.72 $20.23
Resistance Level $54.01 $25.00
Average True Range (ATR) 0.88 1.59
MACD -0.02 -0.24
Stochastic Oscillator 51.02 34.74

Price Performance

Historical Comparison
UVV
DBVT

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: